Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

Elotuzumab is a humanized monoclonal antibody specific for signaling lymphocytic activation molecule-F7 (SLAMF7, also known as CS1, CD319, or CRACC) that enhances natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) of SLAMF7-expressing myeloma cells. This study explored...

Descripción completa

Detalles Bibliográficos
Autores principales: Balasa, Balaji, Yun, Rui, Belmar, Nicole A., Fox, Melvin, Chao, Debra T., Robbins, Michael D., Starling, Gary C., Rice, Audie G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282702/
https://www.ncbi.nlm.nih.gov/pubmed/25287778
http://dx.doi.org/10.1007/s00262-014-1610-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282702/
https://www.ncbi.nlm.nih.gov/pubmed/25287778
http://dx.doi.org/10.1007/s00262-014-1610-3

Ejemplares similares